FDA Orders GLP-1 Labels to Warn of Rare Vision Loss

The FDA will require GLP-1 drugs like Ozempic and Wegovy to warn of NAION, a rare eye condition causing permanent vision loss.

@sharedot

FDA Orders GLP-1 Labels to Warn of Rare Vision Loss

By @sharedot · · 8 pages

  • Health
  • Glp 1
  • Ozempic
  • Wegovy
  • Naion

The FDA will require GLP-1 drugs like Ozempic and Wegovy to warn of NAION, a rare eye condition causing permanent vision loss.

What the FDA is ordering

The FDA has instructed manufacturers of all GLP-1 medications to add information about non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their labels.

The class-wide directive covers Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound, and Sanofi's Soliqua, as reported by The Guardian.

NAION is a rare condition in which blood flow to the front of the optic nerve is suddenly reduced, causing acute, painless vision loss in one eye that can be permanent, according to Fox Business.

The agency began investigating in 2024 after a JAMA Ophthalmology study flagged a possible link between semaglutide and the condition.

What the clinical evidence shows

The FDA reviewed 126 clinical trials involving more than 134,200 patients and identified 15 probable NAION cases: 10 among GLP-1 patients, five among those on placebo, and none among patients on other glucose-lowering medications.

The Guardian reports the agency found roughly 6.4 cases per 100,000 person-years among GLP-1 patients versus 3.8 cases among the comparison group, a roughly 68% higher rate.

The FDA cautioned that the findings do not establish a causal link, and of roughly 78,000 patients studied, just 10 experienced vision loss, approximately 0.01% of participants.

Why causation remains disputed

Both major manufacturers pushed back on any suggestion of proven causation. CNN quotes a Novo Nordisk spokesperson saying the company 'continues to believe the data do not establish a cause-and-effect relationship' and remains confident in the benefit-risk profile of its medicines.

A Lilly spokesperson told CNN the communication applies to all medicines with GLP-1 RA activity and does not reference findings specific to Lilly's drugs.

Risk factors for NAION include diabetes, hypertension, smoking, and sleep apnea, conditions common among GLP-1 patients, making it difficult to separate medication effects from underlying illness.

International regulators moved first

The FDA's action follows earlier signals from overseas. Per CNN, the European Medicines Agency's safety committee said last year that NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year — the first time any regulator confirmed the side effect.

Denmark's Patient Compensation body subsequently granted compensation to four patients who experienced vision loss while taking Novo Nordisk's GLP-1 drugs.

CNN also reports a large 2025 study of nearly 175,000 diabetic patients found the risk of NAION more than doubled after two years of GLP-1 treatment compared with other diabetes drug classes.

Stakes for patients and prescribers

NAION has no proven treatment to reverse the damage, though Fox Business notes research suggests about 43% of patients with significant vision impairment experience some spontaneous improvement, with visual field defects often persisting.

The condition is most common in adults over 50, who often experience sudden, painless vision loss in one eye upon waking, with symptoms including blurred vision, distorted color perception, and blind spots.

Physicians advise patients not to stop their medications abruptly but to seek immediate ophthalmic evaluation for any sudden vision changes, according to Clarin.

What comes next

Citi analyst Geoff Meacham told CNN the FDA action may temporarily increase patient and investor concern, but the rarity of NAION and the substantial weight, glycemic, cardiovascular, renal, and sleep apnea benefits of GLP-1s should preserve a favorable benefit-risk profile and limit changes to prescribing.

Manufacturers must now integrate the disclosure into product packaging and patient guides, with Eli Lilly saying it will respond to the FDA promptly. Analysts expect the warning to raise awareness without derailing the commercial momentum of the blockbuster drug class.

Sources

  1. foxbusiness.com › FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
  2. theguardian.com › FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
  3. cnn.com › US FDA orders new eye risk warnings for Ozempic, Zepbound
  4. clarin.com › GLP-1 blindness warning: FDA orders new label update for Ozempic and Wegovy over rare eye condition NAION

More on Health